Alogliptin Use in Elderly People: A Pooled Analysis from Phase 2 and 3 Studies

@article{Pratley2009AlogliptinUI,
  title={Alogliptin Use in Elderly People: A Pooled Analysis from Phase 2 and 3 Studies},
  author={R. Pratley and T. McCall and P. Fleck and Craig A. Wilson and Q. Mekki},
  journal={Journal of the American Geriatrics Society},
  year={2009},
  volume={57}
}
OBJECTIVES: To compare the efficacy and safety of alogliptin, a dipeptidyl peptidase‐4 (DPP‐4) enzyme inhibitor, in elderly (≥65) and younger (<65) patients with type 2 diabetes mellitus. 
View on Wiley
ncbi.nlm.nih.gov
80 Citations
Highly Influential Citations
4
Background Citations
24
Methods Citations
5
Results Citations
7

Paper Mentions

Interventional Clinical Trial
Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily (QD), combined with pioglitazone in adults with type 2 diabetes mellitus  
ConditionsDiabetes Mellitus
InterventionDrug
Takeda
February 2006 - August 2007
Interventional Clinical Trial
Efficacy and Safety of Alogliptin in Subjects With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily (QD), in adults with type 2 diabetes.  
ConditionsDiabetes Mellitus
InterventionDrug
Takeda
February 2006 - July 2007
Interventional Clinical Trial
Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus.
The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily (QD), combined with a sulfonylurea in adults with type 2 diabetes mellitus.  
ConditionsDiabetes Mellitus
InterventionDrug
Takeda
April 2006 - June 2007
Interventional Clinical Trial
Efficacy and Safety of Alogliptin Combined With Metformin in Participants With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily (QD), combined with metformin in adults with type 2 diabetes mellitus.  
ConditionsDiabetes Mellitus
InterventionDrug
Takeda
March 2006 - June 2007

80 Citations

Citation Type

Citation Type

Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double‐blind, randomized, 1‐year study
Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2‐year study
Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: A multicentre randomized double‐blind placebo‐controlled Phase 3 study in mainland China, Taiwan, and Hong Kong
Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials
Dipeptidyl peptidase‐4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta‐analysis of randomized controlled trials
Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled trial with an open‐label, long‐term extension study
Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled trial with an open‐label long‐term extension study
Predictors of response to dipeptidyl peptidase‐4 inhibitors: evidence from randomized clinical trials
Alogliptin: A DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 34 REFERENCES
Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy
Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin
Individual Sulfonylureas and Serious Hypoglycemia in Older People
Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.
Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP‐4 inhibitors
Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus
Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus
DPP‐4 inhibitors and their potential role in the management of type 2 diabetes
  • A. Barnett
  • Medicine
  • International journal of clinical practice
  • 2006
Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects.
Effects of Intensive Glucose Lowering in Type 2 Diabetes
...
1
2
3
4
...